A Clinical Case of Familial Alopecia Areata in Combination with Immune Pathology
July 2025
in “
Russian Journal of Clinical Dermatology and Venereology
”
Studysummary In this case report, researchers observed that two sisters with congenital immune disorders experienced partial hair regrowth while receiving tofacitinib for severe alopecia areata, highlighting the need for careful clinical and laboratory monitoring due to potential infection risks associated with JAK inhibitor therapy.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The document discusses a clinical case involving two sisters with familial alopecia areata and congenital immune disorders, emphasizing treatment challenges. The older sister, 24, has primary immunodeficiency with selective IgA and IgG2 deficiencies, while the younger sister, 18, is suspected of having an antibody defect. Both are treated with tofacitinib, leading to partial hair regrowth, more notably in the younger sister. The case highlights the need for collaboration among dermatologists, immunologists, and geneticists and suggests potential use of JAK inhibitors, though further research is necessary to validate their effectiveness and safety.
